Study of Ultrasonographic Fatty Liver Indicator and Its Link to Coronary Artery Disease Severity in Adults

What this Trial Is About

Metabolic dysfunction-associated fatty liver disease MAFLD is a condition linked to the development and progression of coronary heart disease CHD. Researchers are studying the relationship between a tool called the ultrasonographic fatty liver indicator US-FLI, which measures liver fat, and the severity of CHD. This observational study aims to better understand how liver fat levels relate to heart disease severity using specific imaging and scoring methods. The study includes 204 patients who had invasive coronary angiography between July 2022 and December 2023. Clinical information and abdominal ultrasound images were collected to assess liver fat using the US-FLI. Patients were classified based on their coronary artery disease CAD status and SYNTAX scores, which measure CHD severity. Groups include non-CAD, CAD with low-risk SYNTAX score 22 or less, and CAD with medium-high-risk SYNTAX score 23 or more. The study uses statistical models to evaluate how US-FLI relates to CHD severity. Participants provide medical and imaging data including ultrasound images and coronary angiography results. The main measurement is the SYNTAX score assessed at baseline. Researchers analyze the accuracy, sensitivity, and specificity of US-FLI to predict CHD severity. The study involves patients aged 18 to 90 years, including those with chest pain or related symptoms, and follows their clinical data retrospectively. The study runs until April 2025 with careful data collection and outcome evaluation.

Positive Association of US-FLI With the Severity of CAD